Cargando…

Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool

BACKGROUND: Rare diseases are defined as life-threatening or chronically debilitating diseases with a prevalence of 50 out of 100,000 individuals or less. Orphan medicinal products (OMPs) are intended for the treatment of rare diseases. The assessment of quality of evidence in small populations is o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Picavet, Eline, Cassiman, David, Aertgeerts, Bert, Simoens, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856624/ https://www.ncbi.nlm.nih.gov/pubmed/24107467 http://dx.doi.org/10.1186/1750-1172-8-157

Ejemplares similares

Clinical evidence for orphan medicinal products-a cause for concern?
por: Picavet, Eline, et al.
Publicado: (2013)

Reimbursement of orphan drugs in Belgium: what (else) matters?
por: Picavet, Eline, et al.
Publicado: (2014)

Shining a light in the black box of orphan drug pricing
por: Picavet, Eline, et al.
Publicado: (2014)

Off-label use of orphan medicinal products: a Belgian qualitative study
por: Dooms, Marc, et al.
Publicado: (2016)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
por: Blonda, Alessandra, et al.
Publicado: (2021)

Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis
por: Vanclooster, Annick, et al.
Publicado: (2016)

Development and Validation of a Tool to Measure Patient Assessment of Clinical Compassion
por: Roberts, Brian W., et al.
Publicado: (2019)

Market access of orphan drugs and the role of multi-criteria decision making
por: Simoens, Steven
Publicado: (2012)

Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
por: Abdallah, Khadidja, et al.
Publicado: (2021)

Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012
por: Pauwels, Kim, et al.
Publicado: (2017)

A Tool to Assess the Trustworthiness of Evidence-Based Point-of-Care Information for Health Care Professionals (CAPOCI): Design and Validation Study
por: Lenaerts, Gerlinde, et al.
Publicado: (2021)

Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
por: Morel, Thomas, et al.
Publicado: (2013)

Registries for orphan drugs: generating evidence or marketing tools?
por: Hollak, Carla E. M., et al.
Publicado: (2020)

The European challenges of funding orphan medicinal products
por: Szegedi, Márta, et al.
Publicado: (2018)

Comparing access to orphan medicinal products in Europe
por: Zamora, Bernarda, et al.
Publicado: (2019)

Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
por: Morel, T., et al.
Publicado: (2016)

How to Assess the Value of Medicines?
por: Simoens, Steven
Publicado: (2010)

Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
por: Brabers, Anne EM, et al.
Publicado: (2011)

Development and validation of the ACE tool: assessing medical trainees’ competency in evidence based medicine
por: Ilic, Dragan, et al.
Publicado: (2014)

Regulatory Standards in Orphan Medicinal Product Designation in the EU
por: Tsigkos, Stelios, et al.
Publicado: (2021)

Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
por: Pontes, Caridad, et al.
Publicado: (2018)

Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation
por: Mulder, Jorn, et al.
Publicado: (2021)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Validation of a 5-Item Tool to Measure Patient Assessment of Clinician Compassion in Hospitals
por: Roberts, Brian W., et al.
Publicado: (2021)

Development and validation of the Body Compassion Questionnaire
por: Beadle, Emily S., et al.
Publicado: (2021)

Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
por: Pijeira Perez, Yankier, et al.
Publicado: (2023)

Not one, but many: developing a multi-indication pricing model for medicines in Belgium
por: Maes, Ingrid, et al.
Publicado: (2023)

Tailoring implementation strategies for evidence-based recommendations using computerised clinical decision support systems: protocol for the development of the GUIDES tools
por: Van de Velde, Stijn, et al.
Publicado: (2016)

Implementing evidence-based medicine in general practice: a focus group based study
por: Hannes, Karin, et al.
Publicado: (2005)

No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
por: Stolk, Pieter, et al.
Publicado: (2009)

Validation of a 5-item tool to measure patient assessment of clinician compassion in the emergency department
por: Sabapathi, Praveen, et al.
Publicado: (2019)

Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study
por: Abdallah, Khadidja, et al.
Publicado: (2022)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
por: Miller, Kathleen L., et al.
Publicado: (2020)

Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia
por: van Overbeeke, Eline, et al.
Publicado: (2021)

Development and validation of a patient-reported measure of compassion in healthcare: the Sinclair Compassion Questionnaire (SCQ)
por: Sinclair, Shane, et al.
Publicado: (2021)

Availability and Accessibility of Orphan Medicinal Products to Patients in Slovakia in the Years 2010–2019
por: Foltanova, Tatiana, et al.
Publicado: (2022)

Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
por: Hughes-Wilson, Wills, et al.
Publicado: (2012)

Downstream activities after laboratory testing in primary care: an exploratory outcome of the ELMO cluster randomised trial (Electronic Laboratory Medicine Ordering with evidence-based order sets in primary care)
por: Piessens, Veerle, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hskdg6v6138iorc411ofd95frk